review describes the progress made in the last five years on the structure, function, and regulation of the ryanodine receptor. Numerous reports have described the response of ryanodine receptors to cellular ions and metabolites, kinases and other proteins, and pharmacological agents. In many cases, comparative measurements have been made using Ca2+ fluxes in SR vesicles, single-channel recordings in planar bilayers, and radioligand binding assays using [3~~ryanodine.
These techniques have.helped to relate the activity of single ryanodine receptors to global changes in the SR Ca2+ permeability.
Molecular information on functional domains within the primary structure of the ryanodine receptor is also available. There are at least three ryanodine receptor isoforms in various tissues. Some cells, such as amphibian muscle cells, express more than a single isoform. The diversity of ligands known to modulate gating and the diversity of tissues known to express the protein suggest that the ryanodine receptor has the potential to participate in many types of cell stimulus-Ca2+-release coupling mechanisms. excitation-contraction coupling; calcium ion-release channel; sarcoplasmic reticulum OGAWA AND EBASHI (147) described the Ca2+-releasing action of nonhydrolyzable ATP analogues in a preparation of isolated skeletal muscle sarcoplasmic reticulum (SR). This ob servation led the authors to suggest that Ca2+ release was not simply the reversal of Ca2+ uptake but a separate and pharmacolo~cally distinct event. The effect of ATP analogues could be demonstrated in SR passively equilibrated with 45Ca2+ (127, 137, 222) and, unlike the Ca2+ pump, was specifically localized to the terminal cisternae (76, 127, 137) . Ca2+ release stimulated by nucleotides shared many features of the Ca2+ release stimulated by micromolar extravesicular Ca2+, also known as Ca2+-induced Ca2+ release. These included stimulation by caffeine (147) and inhibition by procaine (147), ruthenium red (127), and physiological concentrations of Mg2+ (127) . Thus the pharmacological properties of the nucleotide-induced release and the Ca2+-induced release suggested the presence of a single type of terminal cisternae-specific channel, which later became known as the "Ca2+-release" channel. The presence of this channel could also explain the Ca2+-releasing action of a plethora of seemingly unrelated ligands (156) .
Direct recordings of Ca2+-release channels were made by Smith et al. (183) using planar bilayer techniques. Adenine nucleotides increased the open probability and the mean open time of a Ca2+ channel with many unusual properties, such as a large unit conductance and a low ionic selectivity. In addition, the channel displayed sensitivity to Ca2+, ATP, Mg2+, and ruthenium red that were quantitatively adequate to explain the ionic basis of Caz+-induced Ca2+ release (184, 185) . The Ca2+-release channel was also sensitive to the muscleparalyzing alkaloid ryanodine (79, 170) , an observation that was crucial to the identification of the ryanodine receptor as the protein that formed the channel.
The development of a E3H]ryanodine binding assay led to the isolation of the ryanodine-binding protein or ryanodine receptor from homogenates of skeletal muscle (79, 81, 99) . The large molecular mass of the ryanodine receptor monomer, typically in the range of 350,000-450,000 Da, prompted investigators to compare the mor-phological characteristics of the purified protein with the so-called "feet" structures seen at the junction of terminal cisternae and transverse tubular membranes (13, 58, 81) . Th e purified complex consisted of a square or quatrefoil-shaped particle of N 20 nm on each side with a 2nm hole in the center (81, 99, 213) .
This was the characteristic size and shape of the feet structures. Purified ryanodine receptors incorporated into planar bilayers formed Ca2+ -release channels with liganddependent properties similar to those described in native SR vesicles (74, 99, 187) . These observations established that the ryanodine receptor, the Ca2+-release channel, and the foot structure are the same protein. Molecular cloning of the skeletal receptor by Takeshima et al. (201) suggested that the protein structure consisted of a large hydrophilic mass and a short carboxy-terminal region of transmembrane segments. This arrangement was consistent with the foot portion formed by the hydrophylic domain and the pore region formed by the transmembrane domain (201) . Heterologous expression of the ryanodine receptor cDNA showed that the protein formed channels sensitive to Ca2+, adenine nucleotides, and ryanodine (28). Three separate genes identified as ryr-1, ryr-2, and ryr-3 were found to encode ryanodine receptors (125). Expression of these genes did not appear to be tissue specific, but each was predominantly expressed in skeletal muscle, cardiac muscle, or brain and smooth muscle, respectively (66, 116, 153) . Isoform-specific functional domains, such as the cardiac-specific phosphorylation site for Ca2+ / calmodulin-dependent protein kinase (CaM kinase) (2 16), should be useful in determining the regulatory mechanisms of Ca2+ signaling that are dominant in different tissues.
It is the purpose of this review to describe the progress made in the last five years in our understanding of the structure and function of ryanodine receptors. The focus is largely on the protein rather than the signaling mechanisms in which ryanodine receptors participate. Specifically, we have excluded from this review excitationcontraction coupling events within striated muscle cells in which the ryanodine receptor plays a crucial role. In addition, we excluded the participation of ryanodine receptors in pathophysiologies, such as in the clinical syndrome malignant hyperthermia. This information has been reviewed elsewhere (45, 47, 50, 54, 115, 167, 192) . Recent reviews complementary to ours, which focus on other aspects of ryanodine receptors, have also appeared (125, 190) .
CA2+ FLUXEX FROM SR
Ca2+ fluxes have been extensively measured in SR by numerous radioisotopic and nonisotopic techniques. Part of this information was reviewed by Martonosi (119) before the identification of the ryanodine receptor as the major contributor to the flux. Most flux measurements in SR make use of the isotopic tracer 45Ca2+ in protocols consisting of a 45Ca 2+-leading phase followed by a 45Ca2+-release phase. Millimolar concentrations of 45Ca2+ are loaded into the SR lumen by passive diffusion or by active uptake. During the release phase, the myoplasmic surface of the SR is exposed to a "release" solution consisting of micromolar concentrations of free Ca2+ and/or other stimulatory or inhibitory ligands. The kinetics of Ca2+ efflux have been resolved using stoppedflow, quenched-flow, or rapid-filtration techniques. In stopped flow, Ca2+ release induced by a rapid mixing step is monitored continuously using Ca2+ indicator dyes (85, 89, 141) . In quenched flow, mixing of vesicles and a Ca2+-buffered release solution is followed by a sudden termination of the release with a "quenching" solution (127, 130) . In rapid filtration, there is a complete substitution of the extravesicular solution with a release solution while the SR remains bound to a nitrocellulose filter (20, 30, 46, 139, 197) . Rapid filtration differs from quenched flow in that the released Ca2+ and the SR are separated instantaneously.
In quenched flow, separation of the two Ca2+ pools occurs after the release is terminated.
Thus quenched flow relies entirely on the efficiency of the quenching solution, which in the case of SR is usually composed of micromolar concentrations of the dye ruthenium red. In skeletal muscle SR, Ca2+-induced Ca2+ release is stimulated by adenine nucleotides and inhibited by Mg2+ (Table 1 ). The Ca2+ dependence of the efflux rate forms a bell-shaped curve with a maximum near pCa 6 (44, 90, 127, 130, 139, 141, 197) .
Efflux rates decrease as extravesicular free Ca2+ concentrations approach pCa 9 or 3 (20, 90, 96, 127, 130, 139, 141, 147, 197) . Similarly, the rate of Ca2+ release from cardiac SR is a biphasic function of free Ca2+ concentration with the maximum at 5-20 FM Ca 2+ (27 32 131, 169). The bell-shaped Ca2+ dependence of release has been hypothesized to result from different Ca2+-binding sites, a high-affinity site that stimulates Ca2+ release and a low-affinity site that inhibits release (130, 141) . However, it is important to note that a decrease in Ca2+ efflux rate at millimolar extravesicular Ca2+ concentrations may not solely reflect a decrease in SR Ca2+ permeability.
It could also reflect a decrease in Ca2+ driving force as the extravesicular Ca2+ concentration approaches the intravesicular Ca2+ concentration.
The contribution of the decrease in driving force to the Ca2+ efflux rate has not yet been adequately investigated.
Because the estimated cellular free Mg2+ is in the millimolar range (120), the inhibitory effect of Mg2+ may be a significant mechanism for closing ryanodine receptors. In Ca2+ flux protocols, Mg2+ produces a strong inhibition of Ca2+ release (20, 127, 130, 141) , with a half-maximal inhibitory concentration of 70 PM (127, 130). The mechanism of Mg2+ inhibition appears to be a competitive displacement of Ca2+ from the high-affinity stimulatory site (130, 141) . In contrast to its effect on skeletal SR, Mg2+ in the millimolar range does not completely block Ca2+ release in cardiac SR (30, 131, 169) . Adenine, adenosine, and adenine nucleotides (AMP, ADP, and ATP) and nonhydrolyzable ATP analogues, such as P,y-methyleneadenosine 5'-triphosphate (AMP-PCP), have been shown to counteract the inhibition by Mg2+ (20, 127, 130, 139, 141, 197) . For example, Ca2+ release in the presence of 5 mM AMP-PCP was inhibited by 140 PM free Mg2+, which is twice the half-inhibitory Depending on the concentration, ryanodine has been Analysis of ryanodine binding to its receptor site has shown to stimulate or inhibit Ca2+ fluxes in skeletal or provided unique information about channel function. cardiac SR (63, 68, 73, 103, 128, 144, 145 (133, 154, 155, 230) , smooth muscle (227), liver (49, 180, 182) , and epithelial cells (189). Binding of ryanodine is complex, in that there exist both high-and low-affinity binding sites (17, 25, 101, 122, 134, 161, 215 (46, 72, 79, 83, 134, 159) . This was an important finding, since it meant ryanodine could be used as a conformational probe to indicate the gating state of the Ca2+-release channel. This correlation between ryanodine binding and the gating state has held true for many agents (see Table 2 ).
Many studies have indicated that [3H]ryanodine binds in a strictly Ca 2+-dependent manner. Micromolar Ca2+ increases both the affinity of the receptor for ryanodine and the apparent maximum binding capacity (B,,) (159, 160, 163, 175) . The Hill coefficient of the Ca2+-dependent stimulation was -2 (7, 163, 229). Binding of ryanodine to skeletal receptors has a Ca2+ threshold of 0.1-l FM, is optimal at lo-100 PM, and is inhibited at Ca2+ concentrations > 1 mM (18, 31, 134, 159, 160, 210, 229, 230) . The bell-shaped Ca2+ dependence of [3H]ryanodine binding, the Ca 2+ dependence of SR Ca2+ fluxes, and the Ca2+ dependence of ryanodine receptor channel open probability (51) are similar and strongly support a model in which high-and low-affinity Ca2+-binding sites affect binding of ryanodine and opening of the channel (163). Binding of ryanodine to cardiac SR has a Ca2+ threshold of -1 J.JM, is optimal at 10 PM to 1 mM, but, in contrast to skeletal receptors, shows little inhibition at high Ca2+ concentrations (7, 32, 72, 134, 160, 175, 229) . The Ca2+ dependence of the cardiac channel open probability agreed with ryanodine binding data, in that little inhibition of channel activity was observed at millimolar Ca2+ (32). Thus it was suggested that cardiac receptors have a high-affinity Ca2+ activation site but not a low-affinity Ca2+ inhibition site (32). A bell-shaped Ca2+ dependence has been described for Ca2+ fluxes in cardiac SR (32, 131). However, as indicated above, the latter could result from a loss in driving force for Ca2+ efflux when the extravesicular Ca2+ concentration is in the millimolar range. Millimolar Mg 2+ has been shown to effectively inhibit ryanodine binding to skeletal receptors (31, 46, 134, 159, 160, 163) but has little effect on the binding to cardiac receptors (72, 134, 160, 175) . The effect of Mg2+ has been attributed to a decrease in both the apparent B max (134, 163) and th e affinity of the receptor for ryanodine, resulting from a slowing of the ryanodine association rate without a change in the dissociation rate (31). Mg2+ inhibition of ryanodine binding was due to a direct competition between Ca2+ and Mg2+ for the Ca2+ activation site (163) Caffeine in the millimblar range has been found to stimulate
[3H]ryanodine binding to skeletal receptors (31, 46, 228, 229) and, to a lesser extent, to cardiac receptors (72,229). This effect resulted from an increase in the ryanodine association rate without a change in the dissociation rate (31). In the presence of Ca2+ and Mg 2+, caffeine appears to increase the affinity of the activation site for Ca2+ (163). Millimolar concentrations of adenine nucleotides have been shown to stimulate ryanodine binding to skeletal receptors (18, 31, 46, 134, 148, 159, 163, 229) but to have little effect on cardiac receptors (134, 229). The effect of adenine nucleotides seemed to be different from that of caffeine, in that there was little effect of nucleotides on the affinity of the Ca2+ activation site for Ca2+ (163). The stimulation due to adenine nucleotides resulted from an increase in the affinity of the receptor for ryanodine due to an increase in the association rate (31) and/or an increase in the apparent B,, (163). The order of potency in the stimulation of ryanodine binding closely matched that for SR Ca2+ release and was AMP-PCP > adenosine 3',5'-cyclic monophosphate (CAMP) > ADP = adenosine (127,163). Nanomolar ruthenium red inhibited C3H]ryanodine binding to both skeletal (31, 46, 113, 160, 229) and cardiac receptors (72, 160, 175, 229) . Zimanyi et al. (228) have shown that the removal of ruthenium red causes a persistent inhibition of ryanodine binding that can last to 48 h. However, this persistent inhibition could be reversed by the thiol reducing agent, dithiothreitol. Thus it appeared that a shift in the redox equilibrium of critical thiols plays an important role in the inhibition of ryanodine binding by ruthenium red. Thiol groups have also been implicated in the binding of ryanodine and in the gating of channels in the absence of inhibitors (4, 175).
The binding of [3H]ryanodine to skeletal and cardiac SR was stimulated by increasing pH (134,2 lo), temperature (17, 18, 25, 148) , or concentrations of NaCl or KC1 (18, 31, 134, 159, 229) . Th e mechanism by which NaCl or KC1 stimulated binding has been proposed to be either a direct interaction of the salt with the binding site or a shielding of charges on the receptor (134). However, it was recently reported that a similar effect was produced by increasing sucrose concentrations, suggesting that osmolarity and not ionic strength was important (149).
PURIFICATION
The localization of ryanodine receptors specifically to the terminal cisternae of SR was supported by demonstrations that [3H]ryanodine binds to terminal cisternae but not to longitudinal SR (55,83), ryanodine affects SR Ca2+ release from terminal cisternae but not from longitudinal SR (103,176), and ruthenium red enhances Ca2+ loading in terminal cisternae but not longitudinal SR (55, 83, 136, 176) . This enhancement of loading could be abolished by pretreatment of SR with nanomolar concentrations of ryanodine (55, 83). The preparation of well-defined terminal cisternae and the identification of a specific probe, such as [3H]ryanodine, which remains bound to the receptor in SR solubilized in the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio] -1-propanesulfonate (CHAPS), were critical for purification of ryanodine receptors (159, 175).
The detergent-solubilized skeletal ryanodine receptor was purified to homogeneity by sequential heparinagarose chromatography followed by hydroxylapatite chromatography (81), by immunoaffinity chromatography (21, 79), and by density centrifugation through a linear sucrose gradient (99,lO 1). Sodium dodecyl sulfatepolyacrylamide gel electrophoresis of the ryanodine receptor yielded a single band with a molecular mass between 350,000 and 450,000 Da (21, 79, 99, 101) . The actual molecular mass of the receptor, later determined by molecular cloning, was -564,000 Da (201,231). The purified receptor had an apparent sedi mentation coefficient of 3OS, indicating that it was a large tetrameric complex with an estimated molecular mass > lo6 Da (13, 81, 99, 101) . L'k 1 ewise, in gel-exclusion chromatography, the purified receptor eluted as a peak corresponding to a molecular mass > lo6 Da (81).
The CHAPS-solubilized cardiac ryanodine receptor was purified to homogeneity by sequential heparinagarose chromatography followed by p-aminobenzamidine-agarose and gel-permeation chromatography (82), by density gradient centrifugation (9, 107), and by a combination of gel-permeation chromatography and density gradient centrifugation (164). Like that of skeletal ryanodine receptors, the cardiac receptor complex had a sedimentation coefficient of 30s (9). However, Inui et al. (82) found that th e cardiac receptor subunit had a slightly higher mobility on electrophoretic gels, and its molecular mass was later determined, with the use of molecular cloning, to be -565,000 Da (153).
The CHAPS-solubilized brain ryanodine receptor was purified using a combination of heparin-agarose chromatography, ion-exchange chromatography, and density gradient centrifugation (123) and was found, with the use of molecular cloning techniques (66), to be a highmolecular-mass protein of -552,000 Da. This protein was immunologically detected by a polyclonal antibody raised against the carboxy terminus of the skeletal muscle ryanodine receptor and by a polyclonal antibody against the putative CAMP-dependent phosphorylation site of the cardiac ryanodine receptor (123). The purification by size-exclusion chromatography of a 280,000-Da ryanodine-sensitive channel protein from human neutrophils has also been reported (166). A CHAPS-solubilized 30s ryanodine receptor from aortic smooth muscle has been partially purified by density gradient centrifugation (69). Seiler et al. (176) found that high-molecular-mass proteins of junctional SR, later identified as ryanodine receptors, were phosphorylated by an endogenous CaM kinase or by the exogenous catalytic subunit of CAMPdependent protein kinase (PKA). Phosphorylation by these and other kinases was subsequently demonstrated in cardiac (193, 199, 200, 209, 216, 223) and skeletal (33, 196, 199, 214) ryanodine receptors. Takasago et al. (199) observed that, in the presence of the exogenous catalytic subunit of PKA, guanosine 3',5'-cyclic monophosphatedependent protein kinase (PKG), or CaM kinase, phosphorylation of the cardiac ryanodine receptor occurred at similarly rapid rates. In contrast, protein kinase C (PKC)-dependent phosphorylation occurred at a relatively slow rate, even though the final level of 32P incorporation was similar to that seen with PKA and PKG. Additionally, the level of 32P incorporation in the presence of PKA, PKC, or PKG was comparable with the maximal level of [3H]ryanodine binding, indicating a stoichiometry of -1 mol of phosphate per mole of ryanodine binding sites (199) . Thus it appeared that 1 mol of phosphate was incorporated per mole of tetrameric receptor, assuming only one high-affinity ryanodine binding site per tetramer. On the other hand, phosphorylation by exogenous CaM kinase was -4 times greater than that with PKA, PKG, or PKC (199) , suggesting that four phosphorylation sites per tetramer were present for exogenous CaM kinase. However, Witcher et al. (216) (196), or by PKG (196, 199) has been demonstrated. Suko et al. (196) showed that the stoichiometry of phoshorylation to the purified receptor was 0.88 mol phosphate/m01 receptor monomer for PKA, 0.61 mol phosphate/m01 receptor monomer for PKG, or 0.3-0.6 mol phosphate/m01 receptor monomer for CaM kinase. Phosphoamino acid analysis indicated that PKA, PKG, and CaM kinase phosphorylated serine residue 2843. In addition, CaM kinase phosphorylated other unidentified residues, including threonine (196). The observations using CaM kinase or PKA were disputed by a study in which the apparent phosphorylation of the skeletal receptor was due to the phosphorylation of an adventitious protein. This protein migrated with the ryanodine receptor but was unrelated to it since it did not crossreact with antibodies to the skeletal receptor (216). Other studies indicated insignificant or no phosphorylation due to CaM kinase or PKA (193, 199, 200 Ionic selectivity and Ca 2+-dependent gating of ryanodine receptors has been investigated in planar bilayers by fusion of SR (10, 19, 32, 51, 65, (183) (184) (185) 207, 224) or by incorporation of purified ryanodine receptors (74, 107, 109, 112, 187, 220 (Table 3 ). There is little discrimination between Ca2+ and Ba2+, but divalent cations are more permeable than monovalent cations in mixed solutions. The anionic permeability seems to be nonexistent (107,187). The high conductance and low selectivity clearly set the ryanodine receptor apart from Ca2+ channels of plasma membranes, which typically display low conductance and high ionic specificity. However, the ryanodine receptor shares many single-file permeation properties of highly selective channels. The Ca2+ conductance saturates with increasing luminal Ca2 + concentrations, following a simple Michaelis-Menten curve with the parameters maximum conductance (ymax) and dissociation constant (&) equal to 80 S p and 4 mM for the cardiac channel (107) and 172 pS and 3 mM for the skeletal channel, respectively (187). The monovalent cation conductance, measured in the absence of divalent cations, saturates at a much higher value and with a lower affinity. For example, the yrnax and & for K+ are 1 nS and 47 mM for the skeletal channel, respectively (187). Thus the conductance ratio y&ca for the skeletal channel was -6. However, the permeability ratio PK/Pc,, was 0.14 (187). This discrepancy between the conductance ratio, measured in single salts and that favors monovalent cations, and the permeability ratio, measured in mixed salts and that favors divalent cations, was argued to support a conduction mechanism where multiple ion-binding sites are arranged in single file (187). Tinker et al. (205, 207) proposed a four-barrier three-binding site model to Ion conduction in the cardiac channel has been probed with symmetrical tetra-alkyl ammonium cations of the series (CnH2n+l) 4N+ (204, 206) . Small organic cations of n = l-3 added to both sides of the channel produced a strong block of K+ current at cis (myoplasmic)-positive potentials but with little effect on the current at negative potentials. Analysis of the block was consistent with binding of the blocker ion at a single site in the pore located at 50-90% of the electric field depending on the probe size. The affinity of block varied monotonically with the number of methyl and methylene groups in the blocker molecule, supporting the presence of a hydrophobic pocket within the pore to which the organic cations could bind (206). Larger quaternary ammonium derivatives of n = 4 and 5 (204) induced a voltage-dependent subconductance state that was suggested to result from a partial occlusion of the channel by the bulky organic cation. These studies support a model in which the pore has a wide capture radius. Blocker molecules as large as tetraethylammonium can move through the pore for a distance of up to 90% of the electric field across the bilayer (206). Less hydrophobic blocker molecules of equivalent size, such as tris(hydroxymethyl)aminomethane ion with a molecular cross section of -38 A2, produce a small but discernible conductance (187). This pore cross section is consistent with the recently determined pore radius of the cardiac ryanodine receptor of -3.5 A (208). The maximum number of ions able to occupy the channel at a given time is probably one (205, 207) or two (187). Interestingly, in the ryanodinemodified channel, there is a reduction of the capture radius for ion entry that explains the lower conductance of the channel as well as the lower rate of entry of quaternary ammonium blockers (209). Studies of permeation of neutral molecules measured by quenched-flow and light-scattering methods are consistent with the large pore size of the ryanodine receptor (86, 87, 128) . Glucose entry into SR had the same characteristics as Ca2+-induced Ca2+ release, in that it was stimulated by micromolar extravesicular Ca2+, millimolar caffeine, or millimolar ATP and was inhibited by millimolar Mg2 + or micromolar ruthenium red (86, 87, 128) . These results suggested that glucose is capable of permeating the ryanodine receptor. Other nonelectrolytes such as xylose, glycine, and glycerol also permeate the channel (87).
PHOSPHORYLATION
The Ca2+ dependence of the open probability has been investigated by varying the free Ca2+ in the cis-solution while keeping a constant concentration of divalent or monovalent cation as the current carrier in the transsolution. The membrane potential did not influence the Ca2+ dependence of the channel and, in most studies, was held constant near 0 mV. A bell-shaped open probability vs. Ca2 + curve with a maximum at l-10 FM cis free Ca2+ was described for an amphibian skeletal channel with Ca2+ or Ba2+ as the current carrier (19) and for mammalian skeletal channels (rabbit, pig, and human) with Cs+ as the current carrier (51, 52, 179). A sublinear (Hill coefficient < 1) open probability vs. Ca2+ curve that did not saturate as a function of cis free Ca2+ was described for mammalian skeletal (rabbit) and cardiac (sheep) channels with Ca2+ or Ba2+ as the current carrier (10, 185). Finally, a sigmoidal (Hill coefficient -1) open probability vs. Ca2+ curve that saturated at -10 FM cis free Ca2+ was described for both a mammalian cardiac (dog) channel with Cs+ as the current carrier (32, 65) and for an amphibian channel with Ca2+ or Ba2+ as the current carrier (19). The origin of the discrepancy in the Ca2+ dependence of the various Ca2+ -release channels is not entirely clear. In the case of mammalian skeletal channels, the current carrier plays an important role since high trans Ca2+ or Ba2+ was shown to reduce the opening probability of the channel activated by cis Ca2+ (51, 112 (32), the open probability varied with cis free Ca2+ in a sigmoidal fashion with a threshold for channel opening of 0.1 J.LM and saturation at 10 PM cis free Ca 2+. However, in the sheep cardiac channel recorded using Ca2+ as the current carrier (lo), no saturation was described. Although the species are different, it is highly likely that the sublinear Ca2+ dependence and lack of saturation reported for the sheep channel may be due to the current carrier. When mammalian skeletal and cardiac channels were compared in the same solutions, there appeared to be a genuine difference. The Ca 2+ dependence of the skeletal channel was described as a bell-shaped curve, whereas that of the cardiac channel was described as a saturating curve (32).
The Ca2+ dependence of open and closed states of cardiac (10) and skeletal (185) channels was analyzed using 54 mM Ca2+ as the current carrier in the transsolution. The cis free Ca2+ threshold for opening of the skeletal channel was -1 FM, whereas, in the cardiac channel, the threshold for opening was -0.1 FM free Ca2+ (10, 185 10, 29, 51, 74, 99, 100, 109, 165, 169, 183, 185, 187, 224) , millimolar caffeine (52, 105, 109, 168) , and ryanodine concentrations < 10 FM (9, 10, 17, 18, 29, 51, 52, 74, 79, 99, 100, 107, 109, 112, 165, 170, 187, 224) . Decreases in open probability occurred in response to millimolar free Mg2+ (9, 29, 51, 74, 99, 100, 109, 169, 184, 185, 187, 224) , micromolar ruthenium red (9, 29, 51, 74, 99, 100, 105, 107, 169, 183, 185, 187, 224) , micromolar procaine or tetracaine (105, 220, 224) , and ryanodine concentrations > 100 PM (9, 165).
CLONING, EXPRESSION, AND LOCALIZATION
Three different ryanodine receptor genes have been identified in mammals and are designated here as the skeletal, cardiac, and brain ryanodine receptor genes or ryr-1, ryr-2, and ryr-3, respectively (125). In addition to the three mammalian ryanodine receptor genes, part of a homologous gene, called the dry gene, has been cloned from DrosophiZa. The dry and mammalian genes are highly conserved. The dry gene encodes an mRNA of -15 kilobases and is expressed in the somatic muscles and, at a lower level, in neuronal tissues of Drosophila (67). The ge ne for the skeletal muscle ryanodine receptor was specifically localized to region 19q13.1, on the long arm of human chromosome 19 (114), whereas the cardiac ryanodine receptor gene was localized to human chromosome 1 (153). The chromosomal position of the brain gene is currently unknown. Each of the three genes encodes mRNA of -16 kilobases and proteins of -5,000 amino acid residues (66, 142, 153, 201, 231) . The tissue distributions of the three proteins are summarized in Table 4 .
A number of features of the secondary structure are common to the three proteins. A motif of -100 amino acid residues is repeated four times in each case (66, 142, 153, 231 ). An amino-terminal signal sequence is not present in any of the proteins, indicating that the amino terminus is cytoplasmic. The transmembrane (TM) structure of the proteins is somewhat controversial. ecule and 2 additional ones near the center of the found in the human form (231). Based on the 12-TM molecule. Subsequent reports on the cardiac or brain segment model, all of them were located in regions ryanodine receptor seem to subscribe to one or the other predicted to be on the cytoplasmic side of the SR and of the two models (Table 5 ). The amino terminus and were therefore not expected to be glycosylated. Howcentral part of each molecule is hydrophilic and is ever, using the four-TM segment model, one of the therefore believed to form the cytoplasmic foot (201, glycosylation sites was located in the lumen of the SR 231). Putative modulatory sites have been identified in and might therefore be glycosylated (231). The rabbit the amino acid sequence for each protein (see Table 5 ). form contained high-affinity nucleotide-binding seSites that have some, but not all, of the characteristics of quences and high-affinity Ca2+-binding domains of the a nucleotide binding site have been described. The EF-hand type near the first TM segment in the preamino acid sequence GXGXXG, known as a nucleotide dicted cytoplasmic domain. However, these sites bore a binding motif, has been found in all three cases. Howresemblance to but did not have all of the characteristics ever, the secondary structure surrounding each of these of the typical nucleotide binding sites or EF-hands (201, motifs does not match that of high-affinity nucleotide binding sites, except for one sequence reported for the 231). A potential low-affinity Ca2+ binding domain was identified for the human form in a region of cytoplasmic cardiac protein (153).
acidic residues (23 1).
Skeletal Ryanodine Receptor
The cDNA sequences of the ryanodine receptor from human (23 1) or rabbit (20 1,23 1) skeletal muscle demonstrated that the protein consists of 5,032 or 5,037 amino acid residues with molecular masses of 563, 584 or 565, 223 Da (201, 231) , respectively. Regions that may interact with calmodulin were identified in both forms (201, 231) . Potential phosphorylation sites were found in the cytoplasmic region of the human form, just upstream from the probable channel-forming sequences (231). Several possible glycosylation sites were also Information regarding functional Ca2+ binding sites was obtained by studying the binding of 45Ca2+ or ruthenium red, an indicator of Ca2+ binding sites, to various sequences lying between residues 4,014 and 4,765 of the rabbit form (29). Polyclonal antibodies raised against sequence 13~2, lying between residues 4,478 and 4,512, increased the Ca2+ sensitivity of ryanodine receptor channels incorporated into planar bilayers, resulting in an increase in open probability and mean open time without altering the channel conductance. The antibody-activated channel retained its sensitivity to known ryanodine receptor ligands, such as Ca2+ Mg2+, ATP, ryanodine, and ruthenium red. Sequence 13~2 was therefore proposed to be involved in Ca2 + -induced Ca2 + release (29). Two isoforms of the ryanodine receptor in skeletal muscle have been identified in a number of species, including toadfish (150), chicken (5, 150, 198) , and frog (19, 100, 140, 150) . The two isoforms, called (x and p, were found to coexist in the same muscle fiber (5, 150, 198) and could be differentiated by immunological methods (5, 100, 140, 150, 198) and by proteolytic mapping (5, 140, 150). The two isoforms were identified as ryanodine receptors based on their molecular masses (5, 100, 140, 150, 198) , their existence as large homooligomers (5, 100, 140, 150), their ["Hlryanodine binding activities (5, 140, 150, 198) , and their ability to form Ca2+-release channels (19, 100, 140) . Whether the (xand P-isoforms are the result of alternative splicing or expression of different genes is unclear. Immunological techniques identified epitopes in the amphibian a-and P-skeletal isoforms common to the mammalian skeletal and cardiac forms of the receptor, respectively (100). However, in avian striated muscles, a, p, and cardiac isoforms of the ryanodine receptor were shown to correspond to three distinct proteins (6).
Evidence for a functional difference between the w and P-isoforms was obtained from recordings of Ca2+-release channels from frog skeletal muscle SR that displayed two distinct Ca 2+ dependencies (19). About one-half of the recorded channels was blocked by millimolar concentrations of Ca2+ added to the myoplasmicequivalent solution and was called blockable channels. The open probability of these channels exhibited a bell-shaped dependence as a function of the myoplasmic Ca2+ concentration that was typical of mammalian skeletal channels. The other one-half of the recorded channels was not blocked by millimolar Ca2+. The open probability exhibited a sigmoidal dependence as a function of the cytoplasmic Ca2+ concentration that has also been seen in mammalian cardiac channels (32). It was thus suggested that the blockable and nonblockable channels might coincide with the ~1-and p-isoforms, respectively ( 19).
The a-and p-isoforms were identified in muscles from primitive vertebrates, such as sharks, frogs, turtles, and crocodiles. However, only one isoform was identified in muscles from snakes, lizards, and various mammalian species (146). Both the w and p-isoforms were identified in nonspecialized body muscles of fish and birds, whereas only the ar-isoform was found in specialized muscles from these animals, such as the swim bladder muscle in fish and the extraocular muscles in both fish and birds (146). The existence of the <x-isoform alone in muscles that are known for their rapid contractions and that might be considered more advanced when compared with nonspecialized muscles suggested that the loss of the p-isoform resulted from the evolutionary need for fast contractions (146). The cDNA encoding the skeletal form was expressed in Chinese hamster ovary (CHO) cells (157, 201) Single-channel recordings of the COS-lexpressed protein demonstrated that its ligand responses were qualitatively similar to those of the native ryanodine receptor. However, anomalous conductance states were evident in the expressed channel, possibly indicating a difference in posttranslational processing between COS-1 and skeletal muscle cells or the lack of one or more muscle-specific components in COS-1 cells that are required for channel stabilization (28). Expression of the skeletal form was made more complex by the discovery in brain of an -2,400-nucleotide RNA that hybridizes with the 3'-terminal region of the skeletal cDNA. The -2,4OO-nucleotide RNA was found in addition to the full-length skeletal RNA of -16,000 nucleotides.
The -2,400-nucleotide RNA encodes -656 amino acid residues at the carboxy terminus of the receptor and was thus suggested to encode the pore region of the channel (202). Thus it appeared that two transcripts differing in their start sites are produced from the skeletal ryanodine receptor gene in brain.
Cardiac Ryanodine Receptor
The cDNA sequence for the rabbit cardiac ryanodine receptor indicated that the expressed protein was composed of 4,969 (153) or 4,968 or 4,976 (142) Table 5 ).
The with the Ca2+-release channel or with a membrane component tightly associated with the channel. In the absence of ATP, calmodulin reduced the rate of Ca2+ release from skeletal SR by a factor of 2-3 (129) and from cardiac SR by a factor of 3-6 (131). In both tissues, the half-maximal inhibitory concentration of calmodulin was between 0.1 and 0.2 PM, and maximal inhibition was observed at l-5 PM (129,131). Calmodulin inhibited Ca2+-induced Ca2+ release at Ca2+ concentrations between 0.1 and 100 FM without shifting the bell-shaped Ca 2+ dependence of release (129). Trifluoperazine, calmidazolium, and compound 48/80 had no effect on calmodulin inhibition of Ca2+ release at concentrations known to inhibit calmodulin-mediated reactions in other systems (129). Planar bilayer recordings demonstrated that 2 J.LM calmodulin, in the absence of ATP, decreased the mean open time of skeletal and cardiac Ca2 + -release channels by -40% (188). Nanomolar concentrations of calmodulin were shown to inhibit [3H]ryanodine binding to the purified brain receptor (124).
60-kDa Protein
Phosphorylation and dephosphorylation of a 60-kDa protein, presumably an isoform of phosphoglucomutase, was shown to regulate Ca2+ release from skeletal SR (89, 9 1). In parallel studies of the kinetics of Ca2+ /calmodulindependent phosphorylation and the kinetics of Ca2+ release, the level of phosphorylation of the 60-kDa protein was proportional to the extent of inhibition of Ca2+ release (88, 89). There was no effect of phosphorylation on Ca2+ uptake or Ca 2+-dependent ATPase activities (89). Dephosphorylation reversed the inhibition of Ca2+ release (89). However, in a separate study, the time courses of inhibition of Ca2+ release and Ca2+/calmodulin-dependent phosphorylation were not coincidental, suggesting that the two processes were independent WV. Calsequestrin Calsequestrin, the primary Ca2+-binding protein of the SR, undergoes large conformational changes when bound to luminal Ca2+ (1, 22, 39, 135, 152 (84). The discovery of the association of a 12-kDa FKBP (FKBP12) with the ryanodine receptor appears to have been accidental, since 1 of 31 peptides that resulted from the proteolysis of a highly purified ryanodine receptor preparation was mapped to the amino terminus of FKBP12 rather than to the amino acid sequence of the ryanodine receptor (35). Further studies revealed a tight association between the ryanodine receptor and FKBP12. These included copurification through sequential heparin-agarose, hydroxylapatite, and size-exclusion chromatography; coimmunoprecipitation of the ryanodine receptor and FKBP12 with anti-FKBP12 antibodies; and subcellular localization of both proteins to the terminal cisternae of the SR (84). The molar ratio of the FKBP12 to the ryanodine receptor was 4: 1, indicating a stoichiometry of one FKBP12 per receptor monomer (203). The effect of FKBP12 on the SR Ca2+ permeability was investigated using terminal cisternae preparations that were depleted of FKBP12. The FKBP12-depleted vesicles displayed a decreased threshold for caffeine-induced Ca2+ release and a slower rate of Ca2+ uptake that was reversed by micromolar ruthenium red (203). Both results supported a modulatory role of FKBP12 on the ryanodine receptor channel.
106-kDa Protein
The functional properties of a 106-kDa protein from junctional SR has caused debate about the identity of the SR protein responsible for Ca2+-induced Ca2+ release. The 106-kDa protein was purified using biotinavidin chromatography (219,225), immunoaffinity chromatography (7 l), or ryanodine affinity chromatography (172), with no detectable contamination from the ryanodine receptor. Purified 106-kDa proteins, incorporated into planar bilayers, formed large conductance (yNa -365 Ps and YCa -108 pS) cationic channels that were activated by micromolar free Ca2+ (219, 225) or millimolar ATP (71,225) and that were blocked by micromolar ruthenium red (71, 219, 225) or millimolar Mg2+ (71, 225) . The response to ryanodine was variable. Ryanodine increased the open probability at concentrations between 0.5 and 1 nM (71), locked the channel into a closed state at concentrations of 2-10 nM (71, 172), or locked the channel into a subconductance state at a concentration of 10 nM (219). Immunological and biochemical evidence suggested that the 106-kDa protein was not the Ca2+-Mg2+-ATPase of SR or a proteolytic fragment or subunit of the ryanodine receptor (225). A 106-kDa protein was also identified in heart muscle using immunological techniques and ryanodine affinity chromatography (172). The relationship between the 106-kDa protein and the ryanodine receptor remains to be elucidated.
Triadin
Triadin is a 95-kDa SR protein that, in its native state, exists as a sulfide-linked homopolymer (26). Both the solubilized ryanodine receptor and the al-subunit of the dihydropyridine receptor were found to bind triadin in protein overlay and in affinity chromatography experiments (16, 92). Triadin appeared to play a role in excitation-contraction coupling, since a monoclonal antibody to triadin inhibited the slow phase of depolarizationinduced SR Ca2+ release (14). Additional evidence supporting a role for triadin in Ca2+ release included the localization of triadin to the terminal cisternae of the SR (95) and demonstration that the molar content of triadin in SR was approximately the same as that of the ryanodine receptor monomer (26).
Cloning and determination of the amino acid sequence of triadin has led to some controversy regarding the ability of triadin to interact with the dihydropyridine receptor. Analysis of the amino acid sequence and peptide mapping of triadin revealed that triadin is an intrinsic membrane glycoprotein with a single transmembrane domain (94, 95) . The carboxy terminal of triadin was proposed to be on the luminal side of the SR membrane, whereas the amino-terminal 47 amino acids were proposed to form the cytoplasmic domain. Because the latter segment may be too short to interact directly with the dihydropyridine receptor, the physical relationship between triadin and the al-subunit still needs to be resolved (94). An extremely high concentration of basic residues was found in the luminal domain of triadin and was suggested to interact with acidic residues of calsequestrin. This interaction might provide an anchoring point for calsequestrin and possibly a functional connection between calsequestrin and the ryanodine receptor (125). The tissue distribution of triadin is presently unresolved. Immunological and biochemical evidence suggested that a protein similar or identical to triadin was expressed in cardiac muscle (15). However, Northern and Western blots did not support the expression of triadin in cardiac muscle, nor in brain (94). RYANODINE 
RECEPTORS, A SUPERFAMILY OF CA2+-RELEASE CHANNEL PROTEINS
The basic structural and functional features of ryanodine receptors, as presently known, have been derived almost exclusively from studies in skeletal and cardiac muscle. The main cellular event controlled by this protein in muscle is excitation-contraction coupling, i.e., the increase in SR Ca2+ permeability triggered by cell depolarization. However, biochemical, electrophysiological, and molecular studies have demonstrated in a rather dramatic way that ryanodine receptors are a superfamily of intracellular Ca2+ -release channel proteins that is not restricted to tissues that undergo excitation-contraction coupling. Hence we would anticipate that many of the properties of ryanodine receptors presented in this review will probably turn out to be specific for muscle tissues and may not be conserved in tissues dissimilar to muscle. The broad range of nonmuscle tissues in which ryanodine receptors are expressed, ranging from epithelial cells to neurons ( Table  4 ), suggests that ryanodine receptors are suited to participate in stimulus-Ca2+ release coupling mechanisms other than excitation-contraction coupling. Ca2+-induced Ca2+ release, described to various degrees in all ryanodine receptor types, may be one signaling mechanism by which nonmuscle ryanodine receptors could control the Ca2+ permeability of organelles in non- 
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